For many rare disease programs, traditional evidence pathways are not sufficient. Patient populations are small and often heterogeneous, natural history is often incomplete, and clinical data are inherently limited in size and interpretability. In this context, the challenge is often in generating evidence that the FDA can interpret and act on.
Two FDA frameworks are increasingly central to our regulatory discussions: the Plausible Mechanism Pathway to support regulatory decision-making, and the Rare Disease Evidence Principles Pilot. These concepts can get mixed up and are often discussed together, though they serve fundamentally different roles within the development pathway.
Ultimately, both are FDA responses to the same core problem: ultra-rare diseases, tiny datasets, and the unlikelihood of a realistic randomized trial.
Both emphasize mechanism, natural history, and supportive evidence, and both are aimed at settings where traditional randomized controlled trials are not feasible. The difference is that RDEP is an early FDA evidentiary process for qualifying ultra-rare genetic programs, while plausible mechanism is a framework for individualized therapies whose approval case depends on a very tight biologic relationship and a limited clinical dataset.
Below is a side-by-side comparison of both tools:
Plausible Mechanism vs. RDEP
| Question | Plausible mechanism | RDEP |
|---|---|---|
| What is it? | FDA draft guidance/framework for individualized therapies targeting specific genetic conditions with known biological cause | FDA Rare Disease Evidence Principles process run through CDER/CBER |
| Is it something you apply for? | Not in a formal sense. This is a framework/guidance for how to build an approvable package in collaboration with FDA. | Yes. Sponsors may apply to the RDEP process before pivotal trial launch. |
| Main use? | To support approval/licensure of individualized therapies when only limited patient data will be available. | To align early on what evidence FDA may accept for very small, genetically defined rare disease populations |
| Disease/therapy fit? | Specific genetic, cellular, or molecular abnormality; therapy targets the underlying/proximate pathogenic alteration; especially genome editing and RNA-based individualized therapies | Investigational therapy must be specific to correcting the genetic defect or replacing a deficient essential protein; disease generally affects <1,000 U.S. patients and has significant unmet need |
| Evidence logic | Strong biological relationship, untreated natural history, proof of target, clinical improvement, CMC quality | One adequate and well-controlled study, which may be single-arm, plus robust confirmatory/supportive evidence such as mechanistic, biomarker, nonclinical, PD, case-report, expanded access, or natural history data |
| Timing | Most relevant when constructing the approval package for an individualized product where conventional trial design is infeasible | Explicitly pre-pivotal; FDA says sponsors may apply any time before pivotal trial launch |
| Product scope | Narrower and more bespoke/individualized | Broader than individualized but still narrow: ultra-rare, genetically driven, defect-correcting/replacement therapies |
Publicly Disclosed Examples (as of early 2026)
Public examples remain limited given how recently these frameworks have been introduced.
RDEP (Rare Disease Evidence Principles)
- DF-003 (ROSAH syndrome), Drug Farm
- As of March 5, 2026, Drug Farm publicly announced that the FDA accepted DF-003 into the RDEP process for ROSAH syndrome, a rare autoinflammatory disorder caused by gain-of-function mutations in the ALPK1 gene — notably, not a classic protein deficiency, which speaks to the breadth of programs RDEP may accommodate.
Plausible Mechanism Framework
- “Baby KJ”, CPS1 deficiency (personalized CRISPR therapy)
- While not a formal “program entry,” FDA commentary and public discourse consistently point to this case as foundational to how the plausible mechanism approach was shaped.
- Urea Cycle Disorders / Prime Editing Platform, Children's Hospital of Philadelphia (CHOP)
- CHOP has publicly discussed engagement with FDA around an umbrella-style Phase I/II approach for individualized therapies across urea cycle disorder genes. These discussions align with the principles of the plausible mechanism framework, particularly around genetically defined populations and platform-based development.
- Broader individualized therapy efforts
- The FDA has referenced multiple ongoing interactions with sponsors developing n-of-1 or highly targeted genetic therapies, though most have not been publicly named.
Both frameworks are increasingly part of how rare disease programs are being developed and discussed with the FDA, particularly in ultra-rare and genetically defined settings.
We hope this provides clarity as sponsors consider how to apply these frameworks, including how evidence is generated and how programs are positioned as they advance.
If you have questions about how these frameworks may apply to your program, please get in touch with us: contactus@raremoonconsulting.com.